About Exousia Pro
Exousia Pro is a company based in St. Petersburg (United States) founded in 2024 was acquired by Medical Marijuana in January 2025. Exousia Pro has completed 1 acquisition, including Lamy. Exousia Pro offers products and services including Exosome Manufacturing Process and Proprietary Loading Technology. Exousia Pro operates in a competitive market with competitors including Modifi Bio, Biodexa Pharmaceuticals, OncoSynergy, CNS Pharmaceuticals and Plex Pharmaceuticals, among others.
- Headquarter St. Petersburg, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
- Investments & Acquisitions
-
Acquired by
Medical Marijuana
(Jan 06, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Exousia Pro
Exousia Pro offers a comprehensive portfolio of products and services, including Exosome Manufacturing Process and Proprietary Loading Technology.
Patented process using plant-based materials for exosome production.
Technology to infuse molecules like drugs and DNA into exosomes.
Funding Insights of Exousia Pro
Detailed funding history for Exousia Pro
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Exousia Pro
Exousia Pro has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Medical Marijuana.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Manufacturer of cannabis focused products
|
Locked | Locked | Locked |
Investor details for Exousia Pro
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Exousia Pro
Exousia Pro has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Lamy.
Investment portfolio details for Exousia Pro
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
High-quality writing instruments and digital tools are manufactured.
|
Locked | Locked | 1930 | Locked |
Complete acquisition details for Exousia Pro
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Exousia Pro
Detailed financials for Exousia Pro
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Exousia Pro Comparisons
Peer comparison for Exousia Pro
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Exousia Pro
Exousia Pro operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Modifi Bio, Biodexa Pharmaceuticals, OncoSynergy, CNS Pharmaceuticals and Plex Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of cancer
|
|
| Locked | Locked | Locked |
Therapeutics for aggressive rare brain cancers are developed.
|
|
| Locked | Locked | Locked |
Resistance mechanism inhibitors for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Treatments for brain and central nervous system cancers are developed.
|
|
| Locked | Locked | Locked |
Discovering small molecules for diseases caused by protein misfolding such as Parkinson's.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for difficult-to-treat cancers are developed.
|
Detailed competitors of Exousia Pro
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Exousia Pro
Complete news archive for Exousia Pro
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Exousia Pro
Exousia Pro was founded in 2024.
Exousia Pro is headquartered in St. Petersburg, United States. It is registered at St. Petersburg, Florida, United States.
Michael Sheikh is the current CEO of Exousia Pro.
Exousia Pro was founded in 2024 and is based in St. Petersburg, United States. Operations in the biotechnology sector center on exosome-based therapeutics for cancer treatment. A mammalian exosomal technology platform is utilized, incorporating plant-derived materials to engineer exosomes targeted at glioblastoma. Development efforts focus on oncology applications, with leadership directed by CEO Michael Sheikh.
Exousia Pro's top competitors include Modifi Bio, Diakonos and Biodexa Pharmaceuticals.
Exousia Pro offers Exosome Manufacturing Process and Proprietary Loading Technology.
Exousia Pro has made 1 acquisition, including Lamy.
Exousia Pro has 1 investor. Key investors include Medical Marijuana.